Clopidogrel potential in the prevention of cardiovascular events in patients with acute coronary syndromes

American Journal of Cardiovascular Drugs

Volumn 1, Issue 6, 2001, Pages 467-474

  Easthope, Stephanie E ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; TICLOPIDINE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; METHODOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW;

ANGIOPLASTY, BALLOON; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; TICLOPIDINE;

EID: 1842511753     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101060-00006     Document Type: Article

References (42)

1. Savi P, Labouret C, Delesque N, et al. P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001 May 4; 283 (2): 379-83
2. Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999 Aug; 19 (8): 2007-11
3. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 Nov 16; 348 (9038): 1329-39
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000 Sep; 36 (3): 970-1062
5. Yeghiazarians Y, Braunstein JB, Askari A, et al. Unstable angina pectoris. N Engl J Med 2000 Jan 13; 342 (2): 101-14
6. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 Aug 16; 345: 494-502
7. Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000 Aug; 60 (2): 347-77
8. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994 Aug; 72 (2): 313-7
9. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000 Nov; 84 (5): 891-6
10. Savi P, Heilmann E, Nurden P, et al. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemost 1996; 2 (1): 35-42
11. Gachet C, Cazenave JP, Ohlmann P, et al. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochem Pharmacol 1990 Dec 15; 40 (12): 2683-7
12. Klinkhardt U, Kirchmaier CM, Westrup D, et al. Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A. Clin Pharmacol Ther 2000 Mar; 67 (3): 305-13
13. Moshfegh K, Redondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000 Sep; 36: 699-705
14. Altmann C, Welge D, Haude M, et al. Flow cytometric characterization of platelet function and platelet-leukocyte interactions under treatment with clopidogrel in the course of coronary intervention [abstract]. J Am Coll Cardiol 2001 Feb; 37 (Suppl. A): 223
15. Altmann C, Haude M, Welge D, et al. Accelerated inhibition of platelet activation and aggregation after administration of clopidogrel compared to ticlopidine in patients undergoing coronary intervention [abstract]. J Am Coll Cardiol 2001 Feb; 37 (Suppl. A): 32
16. Caplain H, Cariou R. Long-term activity of clopidogrel: a three-month appraisal in healthy volunteers. Semin Thromb Hemost 1999; 25 Suppl 2: 21-4
17. Gawaz M, Seyfarth M, Muller I, et al. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol 2001 Feb 1; 87: 332-6
18. Altmann C, Haude M, Welge D, et al. Reduction of platelet-leukocyte interaction by inhibition of platelet activation after intake of clopidogrel in patients with coronary artery disease [abstract]. Eur Heart J 2000; 30: 21 Suppl.: 657
19. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a frontloaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000 Oct; 20: 2316-21
20. Müller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001 Jan; 85: 92-3
21. Gurbel P. A., Cummings C. C., Alford A. B., et al. Onset and extent of platelet inhibition by loading dose clopidogrel in patients undergoing elective coronary stenting - the PRONTO (Plavix for Reduction of New Thrombus Occurrence) Trial [abstract]. Journal of the American College of Cardiology 2001 Feb; 37 (Suppl. A): 32
22. Karatepe M, Mani A, Soffer D, et al. Clopidogrel loading prior to coronary stent implantation: what is the appropriate dose? Am J Cardiol 2000 Oct 16; 86: 15
23. Roald HE, Barstad RM, Kierulf P, et al. Clopidogrel-a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost 1994 May; 71 (5): 655-62
24. Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000 Jun 20; 101: 2823-8
25. Caplain H, Donat F, Gaud C, et al. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999; 25 Suppl. 2: 25-8
26. Lins R, Broekhuysen J, Necciari J, et al. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin Thromb Hemost 1999; 25 Suppl. 2: 29-33
27. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Prescribing information: Plavix® (clopidogrel bisulfate tablets). 2001 Mar
28. McEwen J, Strauch G, Perles P, et al. Clopidogrel bioavailability: absence of influence of food or antacids. Semin Thromb Hemost 1999; 25 Suppl. 2: 47-50
29. Denninger MH, Necciari J, Serre-Lacroix E, et al. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. Semin Thromb Hemost 1999; 25 (Suppl. 2): 41-5
30. Derya G, Bagnis C, Brouard R, et al. Clopidogrel activities in patients with renal impairment. Clin Drug Invest 1998 Oct; 16 (4): 319-28
31. Slugg PH, Much DR, Smith WB, et al. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol 2000 Apr; 40 (4): 396-401
32. Easton JD. Clinical aspects of the use of clopidogrel, a new antiplatelet agent. Semin Thromb Hemost 1999; 25 Suppl. 2: 77-82
33. Caplain H, D?Honneur G, Cariou R. Prolonged heparin administration during clopidogrel treatment in healthy subjects. Semin Thromb Hemost 1999; 25 Suppl 2: 61-4
34. Lidell C, Svedberg LE, Lindell P, et al. Absence of interaction between clopidogrel and warfarin in patients on long-term anticoagulation. J Am Coll Cardiol 2001 Feb; 37 (Suppl. A): 314
35. Peeters PA, Crijns HJ, Tamminga WJ, et al. Clopidogrel, a novel antiplatelet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interaction. Semin Thromb Hemost 1999; 25 Suppl 2: 51-4
36. Caplain H, Thebault JJ, Necciari J. Clopidogrel does not affect the pharmacokinetics of theophylline. Semin Thromb Hemost 1999; 25 Suppl. 2: 65-8
37. Pierce CH, Houle JM, Dickinson JP, et al. Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. Semin Thromb Hemost 1999; 25 Suppl. 2: 35-9
38. Bhatt DL, Foody JM, Hirsch AT, et al. Complementary additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis [abstract]. J Am Coll Cardiol 2001; 35 Suppl. A: 326
39. CURE Study Investigators. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme: rationale, design and baseline characteristics including a meta-analysis of the effects of the thienopyridines in vascular disease. Eur Heart J 2000 Dec; 21 (No. 24): 2033-41
40. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001 Aug 18; 358: 527-33
41. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000 Aug 8; 102: 624-9
42. Harker LA, Boissel JP, Pilgrim AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999 Oct; 21 (4): 325-35